Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab

被引：0
|
作者：
Aurora, Sheena [1 ]
Oakes, Tina [1 ]
Zhang, Qi [1 ]
Ahl, Jonna [1 ]
Martinez, James [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P2.177
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, Sheena
    Oakes, Tina
    Zhang, Qi
    Ahl, Jonna
    Martinez, James
    NEUROLOGY, 2017, 88
  • [2] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of a Phase II Placebo-Controlled Trial in Patients Treated with Galcanezumab
    Aurora, S. K.
    Oakes, T. M.
    Zhang, Q.
    Ahl, J.
    Martinez, J. M.
    HEADACHE, 2017, 57 : 182 - 183
  • [3] Factors Associated with Significant Reduction in Migraine Headache Days: A Post Hoc Analysis of Phase 3 Placebo-Controlled Trials of Patients with Episodic and Chronic Migraine Treated with Galcanezumab
    Aurora, S.
    Ruff, D.
    Zhang, Q.
    Pearlman, E.
    HEADACHE, 2018, 58 : 163 - 163
  • [4] Factors associated with significant reduction in migraine headache days: a post hoc analysis of phase 3 placebo-controlled trials of patients with episodic and chronic migraine treated with galcanezumab
    Aurora, Sheena K.
    Ruff, Dustin D.
    Zhang, Qi
    Pearlman, Eric M.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [5] A POST HOC ANALYSIS OF FACTORS ASSOCIATED WITH SIGNIFICANT REDUCTION IN MIGRAINE HEADACHE DAYS FROM THREE PHASE 3 PLACEBO-CONTROLLED TRIALS OF PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE TREATED WITH GALCANEZUMAB
    Aurora, S. K.
    Ruff, D. D.
    Zhang, Q.
    Pearlman, E. M.
    CEPHALALGIA, 2018, 38 : 81 - 82
  • [6] Effect of galcanezumab on migraine headache days in women with menstrual migraine: A post hoc analysis
    MacGregor, E.
    Okonkwo, R.
    Fernandes, M. F.
    Rettiganti, M.
    Detke, H.
    Pavlovic, J. M.
    HEADACHE, 2021, 61 : 87 - 88
  • [7] Medication Overuse in a Post-hoc Analysis of Phase 3 Placebo-controlled Studies of Galcanezumab in the Prevention of Episodic and Chronic Migraine
    Aurora, S. K.
    Ruff, D.
    Pearlman, E. M.
    HEADACHE, 2019, 59 : 23 - 23
  • [8] Annual indirect cost savings associated with galcanezumab versus placebo in patients with migraine: Post hoc analysis of phase 3 clinical trials
    Varnado, O. J.
    Ye, W.
    Mi, X.
    Burge, R.
    Hall, J. A.
    HEADACHE, 2022, 62 : 102 - 103
  • [9] Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache
    Andrews, J. Scott
    Kudrow, David
    Rettiganti, Mallikarjuna
    Oakes, Tina
    Bardos, Jennifer N.
    Wenzel, Richard
    Kuruppu, Dulanji K.
    Gaul, Charly
    Martinez, James M.
    JOURNAL OF PAIN RESEARCH, 2021, 14 : 2059 - 2070
  • [10] Post-hoc outcomes from a Phase 3 randomized, double-blind, placebo-controlled study of galcanezumab in patients with episodic cluster headache
    Kudrow, David
    Oakes, Tina
    Bardos, Jennifer
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Zhou, Chunmei
    Riesenberg, Robert
    Wenzel, Richard
    Kuruppu, Dulanji
    Martinez, James
    CEPHALALGIA, 2019, 39 : 60 - 60
12345